APA (7th ed.) Citation

Jurgens, E. M., Firestone, R. S., Chaudhari, J., Hosszu, K., Devlin, S. M., Shah, U. A., . . . Mailankody, S. (2025). Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis. Journal of clinical oncology, 43(5), 498. https://doi.org/10.1200/JCO-24-01785

Chicago Style (17th ed.) Citation

Jurgens, Eric M., et al. "Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis." Journal of Clinical Oncology 43, no. 5 (2025): 498. https://doi.org/10.1200/JCO-24-01785.

MLA (9th ed.) Citation

Jurgens, Eric M., et al. "Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis." Journal of Clinical Oncology, vol. 43, no. 5, 2025, p. 498, https://doi.org/10.1200/JCO-24-01785.